Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN, Rutenberg MS, Hoppe BS, Mohindra P, Larson G, Hartsell WF, Tsai H, Zeng J, Rengan R, Glass E, Katz S, Vargas C, Feigenberg SJ, Simone CB 2nd. Badiyan SN, et al. Among authors: mohindra p. Pract Radiat Oncol. 2019 Jul-Aug;9(4):280-288. doi: 10.1016/j.prro.2019.02.008. Epub 2019 Feb 23. Pract Radiat Oncol. 2019. PMID: 30802618
Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.
Diwanji TP, Mohindra P, Vyfhuis M, Snider JW 3rd, Kalavagunta C, Mossahebi S, Yu J, Feigenberg S, Badiyan SN. Diwanji TP, et al. Among authors: mohindra p. Transl Lung Cancer Res. 2017 Apr;6(2):131-147. doi: 10.21037/tlcr.2017.04.04. Transl Lung Cancer Res. 2017. PMID: 28529896 Free PMC article. Review.
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Scilla KA, et al. Among authors: mohindra p. Oncologist. 2017 Jun;22(6):737-742. doi: 10.1634/theoncologist.2016-0443. Epub 2017 May 22. Oncologist. 2017. PMID: 28533476 Free PMC article.
Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen SM, Badiyan S, Carr SR, Friedberg J, Simone CB 2nd, Edelman MJ, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: mohindra p. Adv Radiat Oncol. 2017 Jul 31;2(3):259-269. doi: 10.1016/j.adro.2017.07.009. eCollection 2017 Jul-Sep. Adv Radiat Oncol. 2017. PMID: 29114590 Free PMC article.
Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: mohindra p. Lung Cancer. 2017 Dec;114:44-49. doi: 10.1016/j.lungcan.2017.10.016. Epub 2017 Nov 2. Lung Cancer. 2017. PMID: 29173764
Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: mohindra p. Lung Cancer. 2018 Feb;116:105. doi: 10.1016/j.lungcan.2017.12.011. Epub 2017 Dec 27. Lung Cancer. 2018. PMID: 29289353 No abstract available.
Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue JM, Feliciano J, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: mohindra p. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):445-452. doi: 10.1016/j.ijrobp.2018.02.003. Epub 2018 Feb 13. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559292
Advances in proton therapy in lung cancer.
Vyfhuis MAL, Onyeuku N, Diwanji T, Mossahebi S, Amin NP, Badiyan SN, Mohindra P, Simone CB 2nd. Vyfhuis MAL, et al. Among authors: mohindra p. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618783878. doi: 10.1177/1753466618783878. Ther Adv Respir Dis. 2018. PMID: 30014783 Free PMC article. Review.
122 results